Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells

Eur J Pharmacol. 2017 Aug 15:809:32-41. doi: 10.1016/j.ejphar.2017.05.015. Epub 2017 May 10.

Abstract

It has been reported that glucagon-like peptide-1 (GLP-1) agents have been associated with both the increased risk of cancer and inhibition of tumor growth and metastases. The aim of this study is to evaluate the effect of liraglutide on hepatocellular carcinoma cells - HepG2. Cytometry was used to evaluate mechanism related to decreased cell proliferation. Nuclear staining and morphometric analysis were also used to verify the process that was taking place after treatment with liraglutide, and in order to better understand the mechanism, TGF-β1 was performed. HepG2 cells decreased proliferation after liraglutide treatment without altering oxidative stress levels. Liraglutide was able to induce autophagy and senescence through the increase of TGF-β1 which possibly explains the growth decrease. We have demonstrated that liraglutide has an antiproliferative effect in HepG2 cells inducing autophagy and senescence by the increase of TGF-β1.

Keywords: Autophagy; HepG2; Hepatocellular carcinoma; Liraglutide; Senescence; TGF-β1.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Autophagy / drug effects*
  • Cell Cycle Checkpoints / drug effects
  • Cell Proliferation / drug effects
  • Cellular Senescence / drug effects*
  • Hep G2 Cells
  • Humans
  • Liraglutide / pharmacology*
  • Mice
  • Signal Transduction / drug effects
  • Transforming Growth Factor beta / pharmacology

Substances

  • Transforming Growth Factor beta
  • Liraglutide